{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:35:37Z","timestamp":1794533737272,"version":"4.9.1"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Views"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/heartviews.heartviews_20_20","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T03:01:20Z","timestamp":1593399680000},"page":"97","source":"Crossref","is-referenced-by-count":17,"title":["PCSK9 monoclonal antibodies: An overview"],"prefix":"10.4103","volume":"21","author":[{"given":"Rasha","family":"Kaddoura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassant","family":"Orabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AmarM","family":"Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1995-705X.288322-1","first-page":"pii:e006910","volume-title":"Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: A meta-analysis of 35 randomized controlled trials?","author":"Karatasakis","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"key-10.4103\/1995-705X.288322-2","first-page":"e001800","volume-title":"Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: A retrospective analysis","author":"Jones","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"key-10.4103\/1995-705X.288322-3","first-page":"2387","volume-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1995-705X.288322-4","first-page":"314","volume-title":"The evolving future of PCSK9 inhibitors","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.288322-5","first-page":"1131","volume-title":"2017 Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia","author":"Landmesser","year":"2018","journal-title":"Eur Heart J"},{"key":"key-10.4103\/1995-705X.288322-6","first-page":"e285","volume-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.288322-7","unstructured":"Pfizer Press Release. Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor. November, 2016. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release detail\/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor. [Last accessed on 2020 Feb 11]."},{"key":"key-10.4103\/1995-705X.288322-8","first-page":"3","volume-title":"A phase I randomized study of a specifically engineered, pH-sensitive PCSK9 inhibitor RN317 (PF-05335810) in hypercholesterolemic subjects on statin therapy","author":"Levisetti","year":"2017","journal-title":"Clin Transl Sci"},{"key":"key-10.4103\/1995-705X.288322-9","first-page":"185","volume-title":"Population pharmacokinetics (PK) and pharmacodynamics (PD) analysis of LY3015014, a monoclonal antibody to protein convertase subtilisin\/kexin type 9 (PCSK9) in healthy subjects and hypercholesterolemia patients","author":"Shen","year":"2017","journal-title":"Pharm Res"},{"key":"key-10.4103\/1995-705X.288322-10","first-page":"881","volume-title":"Modeling and simulation to support phase 2 dose selection for RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin\/kexin type 9","author":"Budha","year":"2015","journal-title":"AAPS J"},{"key":"key-10.4103\/1995-705X.288322-11","first-page":"503","volume-title":"A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin\/kexin type 9","author":"Baruch","year":"2017","journal-title":"Clin Cardiol"},{"key":"key-10.4103\/1995-705X.288322-12","first-page":"179","volume-title":"The PCSK9 revolution: Current status, controversies, and future directions","author":"Warden","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"key-10.4103\/1995-705X.288322-13","first-page":"1108","volume-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1995-705X.288322-14","first-page":"1888","volume-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: Results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","author":"Dias","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.288322-15","doi-asserted-by":"crossref","unstructured":"Gumbiner B, Joh T, Liang H, Wan H, Levisetti M, Vana AM, et al. The effects of single- and multiple-dose administration of bococizumab (RN316\/PF-04950615), a humanized IgG2\u0394a monoclonal antibody binding proprotein convertase subtilisin\/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. Cardiovasc Ther 2018;36:doi: 10.1111\/1755-5922.12309.","DOI":"10.1111\/1755-5922.12309"},{"key":"key-10.4103\/1995-705X.288322-16","first-page":"1891","volume-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1995-705X.288322-17","first-page":"2344","volume-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.288322-18","first-page":"29","volume-title":"Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"key-10.4103\/1995-705X.288322-19","first-page":"56","volume-title":"Efficacy and safety of alirocumab in Japanese subjects (phase 1 and 2 studies)","author":"Teramoto","year":"2016","journal-title":"Am J Cardiol"},{"key":"key-10.4103\/1995-705X.288322-20","first-page":"1212","volume-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","author":"Ballantyne","year":"2015","journal-title":"Am J Cardiol"},{"key":"key-10.4103\/1995-705X.288322-21","doi-asserted-by":"crossref","unstructured":"Fazio S, Robertson DG, Joh T, Wan H, Riel T, Forgues P, et al. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin\/kexin type 9, in hypercholesterolemic subjects on high-dose statin. Cardiovasc Ther 2018;36: doi: 10.1111\/1755-5922.12308.","DOI":"10.1111\/1755-5922.12308"},{"key":"key-10.4103\/1995-705X.288322-22","first-page":"1496","volume-title":"Efficacy and safety of bococizumab (RN316\/PF-04950615), a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, in hypercholesterolemic Japanese subjects receiving a stable dose of atorvastatin or treatment-naive- results from a randomized, placebo-controlled, dose-ranging study","author":"Yokote","year":"2017","journal-title":"Circ J"},{"key":"key-10.4103\/1995-705X.288322-23","first-page":"1995","volume-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"key-10.4103\/1995-705X.288322-24","first-page":"2007","volume-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"key-10.4103\/1995-705X.288322-25","first-page":"2408","volume-title":"Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"key-10.4103\/1995-705X.288322-26","first-page":"1073","volume-title":"Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk\u2014primary results from the phase 2 YUKAWA study","author":"Hirayama","year":"2014","journal-title":"Circ J"},{"key":"key-10.4103\/1995-705X.288322-27","first-page":"1870","volume-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"key-10.4103\/1995-705X.288322-28","first-page":"40","volume-title":"A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk","author":"Kiyosue","year":"2016","journal-title":"Am J Cardiol"},{"key":"key-10.4103\/1995-705X.288322-29","first-page":"341","volume-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"key-10.4103\/1995-705X.288322-30","first-page":"331","volume-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"key-10.4103\/1995-705X.288322-31","first-page":"2531","volume-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.288322-32","first-page":"pii:e003421","volume-title":"Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: The ODYSSEY CHOICE II study","author":"Stroes","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"key-10.4103\/1995-705X.288322-33","first-page":"1781","volume-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial","author":"Leiter","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/1995-705X.288322-34","first-page":"1479","volume-title":"Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial","author":"Ray","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/1995-705X.288322-35","first-page":"162","volume-title":"A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)","author":"Koh","year":"2018","journal-title":"J Clin Lipidol"},{"key":"key-10.4103\/1995-705X.288322-36","first-page":"662","volume-title":"Alirocumab in high-risk patients: Observations from the open-label expanded use program","author":"Glueck","year":"2018","journal-title":"J Clin Lipidol"},{"key":"key-10.4103\/1995-705X.288322-37","first-page":"906","volume-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"key-10.4103\/1995-705X.288322-38","first-page":"1809","volume-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1995-705X.288322-39","first-page":"1980","volume-title":"Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins- ODYSSEY JAPAN randomized controlled trial","author":"Teramoto","year":"2016","journal-title":"Circ J"},{"key":"key-10.4103\/1995-705X.288322-40","doi-asserted-by":"crossref","unstructured":"Roth EM, Moriarty PM, Bergeron J, Langslet G, Manvelian G, Zhao J, et al. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis 2016;254:254-62.","DOI":"10.1016\/j.atherosclerosis.2016.08.043"},{"key":"key-10.4103\/1995-705X.288322-41","first-page":"473","volume-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"key-10.4103\/1995-705X.288322-42","first-page":"2996","volume-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"key-10.4103\/1995-705X.288322-43","first-page":"307","volume-title":"Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program","author":"Farnier","year":"2018","journal-title":"Atherosclerosis"},{"key":"key-10.4103\/1995-705X.288322-44","first-page":"1186","volume-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"key-10.4103\/1995-705X.288322-45","first-page":"3140","volume-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","author":"Bays","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/1995-705X.288322-46","first-page":"138","volume-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"key-10.4103\/1995-705X.288322-47","first-page":"27","volume-title":"ODYSSEY MONO: Effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks","author":"Roth","year":"2015","journal-title":"Future Cardiol"},{"key":"key-10.4103\/1995-705X.288322-48","doi-asserted-by":"crossref","unstructured":"Lorenzatti AJ, Eliaschewitz FG, Chen Y, Lu J, Baass A, Monsalvo ML, et al. Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial. Diabetes Obes Metab 2019;21:1455-63.","DOI":"10.1111\/dom.13680"},{"key":"key-10.4103\/1995-705X.288322-49","first-page":"2452","volume-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.288322-50","first-page":"2541","volume-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.288322-51","first-page":"1580","volume-title":"Efficacy and tolerability of evolocumab vs.ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"key-10.4103\/1995-705X.288322-52","first-page":"758","volume-title":"Efficacy and safety of alirocumab vs.ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"key-10.4103\/1995-705X.288322-53","first-page":"565","volume-title":"Long-term evolocumab in patients with familial hypercholesterolemia","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.288322-54","first-page":"1328","volume-title":"Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies","author":"Stroes","year":"2018","journal-title":"Clin Cardiol"},{"key":"key-10.4103\/1995-705X.288322-55","first-page":"1489","volume-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1995-705X.288322-56","first-page":"1500","volume-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1995-705X.288322-57","first-page":"1713","volume-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1995-705X.288322-58","first-page":"1527","volume-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1995-705X.288322-59","first-page":"2097","volume-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1995-705X.288322-60","first-page":"277","volume-title":"Long-term efficacy and safety of proprotein convertase subtilisin\/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials","author":"Bai","year":"2018","journal-title":"J Clin Lipidol"},{"key":"key-10.4103\/1995-705X.288322-61","first-page":"2373","volume-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"key-10.4103\/1995-705X.288322-62","first-page":"364","volume-title":"Cholesterol-lowering agents PCSK9 inhibitors today and tomorrow","author":"Rosenson","year":"2019","journal-title":"Circ Res"},{"key":"key-10.4103\/1995-705X.288322-63","first-page":"1517","volume-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1995-705X.288322-64","first-page":"633","volume-title":"Cognitive function in a randomized trial of evolocumab","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1995-705X.288322-65","doi-asserted-by":"crossref","unstructured":"Chen Q, Wu G, Li C, Qin X, Liu R, Zhang M. Safety of proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies in regard to diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs 2019. doi: 10.1007\/s40256-019-00386-w.","DOI":"10.1007\/s40256-019-00386-w"},{"key":"key-10.4103\/1995-705X.288322-66","first-page":"2981","volume-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies","author":"Colhoun","year":"2016","journal-title":"Eur Heart J"},{"key":"key-10.4103\/1995-705X.288322-67","first-page":"2132","volume-title":"Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia","author":"Koren","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1995-705X.288322-68","first-page":"98","volume-title":"Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome","author":"Blom","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/1995-705X.288322-69","first-page":"1521","volume-title":"Effect of the proprotein convertase subtilisin\/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus","author":"Sattar","year":"2017","journal-title":"Am J Cardiol"},{"key":"key-10.4103\/1995-705X.288322-70","first-page":"941","volume-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: A prespecified analysis of the FOURIER randomised controlled trial","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key-10.4103\/1995-705X.288322-71","first-page":"731","volume-title":"Effects of evolocumab on Vitamin E and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study","author":"Blom","year":"2015","journal-title":"Circ Res"}],"container-title":["Heart Views"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:48:16Z","timestamp":1786733296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/HEARTVIEWS.HEARTVIEWS_20_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["288322"],"URL":"https:\/\/doi.org\/10.4103\/heartviews.heartviews_20_20","relation":{},"ISSN":["1995-705X"],"issn-type":[{"value":"1995-705X","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}